You are here

Rapid determination of complement activation in the battlefield

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-05-C-0072
Agency Tracking Number: O043-H09-3053
Amount: $99,997.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: OSD04-H09
Solicitation Number: 2004.3
Timeline
Solicitation Year: 2004
Award Year: 2005
Award Start Date (Proposal Award Date): 2005-01-11
Award End Date (Contract End Date): 2006-01-11
Small Business Information
111 Downey Street
Norwood, MA 02062
United States
DUNS: 076603836
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Michael Wilson
 Senior Scientist
 (781) 769-9450
 mwilson@eiclabs.com
Business Contact
 R. Rauh
Title: President
Phone: (781) 769-9450
Email: drauh@eiclabs.com
Research Institution
N/A
Abstract

The objective of this program is to develop an antibody microarray to facilitate the rapid evaluation of complement activation in injured personnel in the battlefield. Soldiers in the battlefield may sustain multiple types of injury, including trauma, hemorrhage, shock, ischemia, burn, and exposure to toxic substances. These conditions are associated with varying degrees of complement activation, which in turn may lead to further deterioration, if left untreated. Moreover, complement is central to normal physiological defenses against microbial infections, and knowledge of the extent of complement activation will aid in determining its proportional inhibition. The proposed antibody microarray would aid the health care professional to evaluate various parameters in injured personnel, including the extent of complement activation, the specific complement pathway that is activated, whether complement inhibitors should be administered, the type of inhibitor to administer, depending on the complement pathway involved, and the dose of inhibitor to be administered. At EIC Laboratories we have developed methods for fabricating immunological electrode sensors based on antibodies immobilized in a hydrous 3-dimensional iridium oxide matrix. In the Phase I program we will construct a prototype antibody array for the electrochemical detection of two different complement proteins.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government